Wong, Wan Ling et al, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040L a systematic review and meta-analysis. The Lancet Global Health, Vol. 2, Issue 2, e106-e116.
Chew, EY, Schachat AP, Should we add screening of age-related macular degeneration to current screening programs for diabetic retinopathy? Ophthalmology. 2015 Dec; 122 (12): 2490-6.
Brown, MM et al. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol. 2005 Jun; 40(3): 277-87.
The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of highdose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
Age-Related Eye Disease Study 2 Research Group. Lutein þ zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309: 2005-15.
Age-Related Eye Disease Study Research Group. Potential public health impact of age-related eye disease results. AREDS report no. 11. Arch Ophthalmol 2003;121:1621-4.
Gupta OP, Brown GC, Brown MM. Age-related macular degeneration: the costs to society and the patient. Curr Opin Ophthalmol 2007;18:201-5.
